1. Adachi T, Hinoi T, Egi H, Shimomura M, Ohdan H. Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery. Surg Today. 2015;45:986–92. https://doi.org/10.1007/s00595-014-1017-y.
2. Ambrose N, MacDonald F, Young J, Thompson H, Keighley M. Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer–can monoclonal antibodies do better? Eur J Surg Oncol. 1989;15:99–102.
3. Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;122:213–21. https://doi.org/10.1002/cncr.29744.
4. Averbach A, Jacquet P, Sugarbaker P. Surgical technique and colorectal cancer: impaction on local recurrence and survival. Tumori. 1994;81(3 Suppl):65–71.
5. Bachleitner-Hofmann T, Zitt M, Jäger T, et al. (ACO-ASSO), f. d. A. P. M. d. Ö. G. f. C. O. Leitlinie zur Behandlung von Patienten mit peritonealen Neoplasmen mittels zytoreduktiver Chirurgie und hyperthermer intraperitonealer Chemotherapie in Österreich 2013. www.aco-asso.at/arbeitsgruppen/ag-peritoneale-malignome/leitlinie-zur-behandlung-von-patienten-mit-peritonealen-neoplasmen-mittels-zytoreduktiver-chirurgieund-hyperthermer-intraperitonealer-chemotherapiein-oesterreich/